@article{fdi:010053758,
  title = {{T}he acute phase of chikungunya virus infection in humans is associated with strong innate immunity and {T} {CD}8 cell activation},
  author = {{W}auquier, {N}. and {B}ecquart, {P}ierre and {N}koghe, {D}. and {P}adilla, {C}. and {N}djoyi-{M}biguino, {A}. and {L}eroy, {E}ric},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground. {R}apidly spreading to new regions, including the islands of the {I}ndian {O}cean, {C}entral {A}frica, and {E}urope, {C}hikungunya fever is becoming a major problem of public health. {U}nlike other members of the alphavirus genus, immune responses to {C}hikungunya virus ({CHIKV}) have been poorly investigated. {M}ethods. {W}e conducted a large ex vivo multiplex study of 50 cytokine, chemokine, and growth factor plasma profiles in 69 acutely infected patients from the {G}abonese outbreak of 2007. {W}e also assessed a phenotypic study of {T} lymphocyte responses during human acute {CHIKV} infection. {R}esults. {CHIKV} infection in humans elicited strong innate immunity involving the production of numerous proinflammatory mediators. {I}nterestingly, high levels of {I}nterferon ({IFN}) alpha were consistently found. {P}roduction of interleukin ({IL}) 4, {IL}-10, and {IFN}-gamma suggested the engagement of the adaptive immunity. {T}his was confirmed by flow cytometry of circulating {T} lymphocytes that showed a {CD}8+ {T} lymphocyte response in the early stages of the disease, and a {CD}4+ {T} lymphocyte mediated response in the later stages. {F}or the first time to our knowledge, we found evidence of {CD}95-mediated apoptosis of {CD}4+ {T} lymphocytes during the first 2 days after symptoms onset, ex vivo. {C}onclusions. {T}ogether, our findings suggest that strong innate immunity is required to control {CHIKV} infection.},
  keywords = {},
  booktitle = {},
  journal = {{J}ournal of {I}nfectious {D}iseases},
  volume = {204},
  numero = {1},
  pages = {115--123},
  ISSN = {1537-6613},
  year = {2011},
  DOI = {10.1093/infdis/jiq006},
  URL = {https://www.documentation.ird.fr/hor/fdi:010053758},
}